Australian researchers have identified an association between nocturnal hypoxia and neovascular age-related degeneration (nAMD). 1 Acting on this realization could prevent nAMD in some patients, ...

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar ...

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas. The US Food and Drug Administration (FDA) has accepted the revised ...

Several pharmaceutical companies have announced new appointments of executives and board members as they prepare for growth in 2025. With the start of 2025, many companies have evaluated the skills ...

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...

Panelists discuss how successful port delivery system (PDS) implantation requires careful patient selection and meticulous surgical technique to minimize complications like vitreous hemorrhage and ...

Turkish researchers reported that optical coherence tomography (OCT) and OCT angiography (OCTA) provide objective supplementary measurements of the retinal nerve fiber layer (RNFL), macular ganglion ...

The Korea Institute of Science and Technology (KIST) has entered into a technology transfer agreement with Huons BioPharma for the development and commercialization of a peptide treatment for dry ...

Video content above is prompted by the following: Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating ...

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed. With the busy holiday season and the winter ...

The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company ...